2,000 Shares in Eli Lilly And Co (LLY) Acquired by Drexel Morgan & Co.
Drexel Morgan & Co. acquired a new position in shares of Eli Lilly And Co (NYSE:LLY) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,000 shares of the company’s stock, valued at approximately $215,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Eli Lilly And Co during the second quarter worth $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Eli Lilly And Co during the second quarter worth $114,000. Fort L.P. bought a new position in Eli Lilly And Co during the second quarter worth $121,000. Welch Group LLC bought a new position in Eli Lilly And Co during the third quarter worth $123,000. Finally, Financial Management Professionals Inc. bought a new position in Eli Lilly And Co during the second quarter worth $128,000. Institutional investors own 76.91% of the company’s stock.
In other Eli Lilly And Co news, major shareholder Eli & Co Lilly sold 700,000 shares of the firm’s stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the transaction, the insider now directly owns 3,148,647 shares of the company’s stock, valued at $44,081,058. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 6,000 shares of the firm’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the completion of the transaction, the senior vice president now directly owns 55,224 shares in the company, valued at $5,870,863.44. The disclosure for this sale can be found here. Insiders sold 1,932,900 shares of company stock worth $142,623,245 over the last ninety days. Insiders own 0.11% of the company’s stock.
Eli Lilly And Co stock opened at $115.81 on Tuesday. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $116.61. The firm has a market capitalization of $120.58 billion, a price-to-earnings ratio of 27.06, a price-to-earnings-growth ratio of 1.78 and a beta of 0.29. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same period last year, the firm earned $1.05 earnings per share. The business’s quarterly revenue was up 7.1% compared to the same quarter last year. Equities research analysts predict that Eli Lilly And Co will post 5.58 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a dividend yield of 1.94%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.
TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/11/20/2000-shares-in-eli-lilly-and-co-lly-acquired-by-drexel-morgan-co.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: Cost of equity and a company’s balance sheet
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.